PolyPid (NASDAQ:PYPD) Announces Earnings Results, Misses Estimates By $1.15 EPS

Key Points

• PolyPid reported a quarterly loss of $0.24 per share, missing analysts’ consensus estimate of $0.91 per share by $1.15.
• The FDA’s priority-review decision date for D-PLEX100 is November 28. The company and Azurity are preparing for a potential U.S. launch in early 2027, subject to FDA approval; hospital adoption may take several months.
• PolyPid said its $15.5 million in quarter-end cash and deposits, along with a $15 million Azurity payment received in October, are expected to fund operations into 2028. It also plans to discuss expanding D-PLEX100’s use to broader abdominal procedures with the FDA.

PolyPid (NASDAQ:PYPD - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of $0.91 by ($1.15), FiscalAI reports.

Here are the key takeaways from PolyPid's conference call:

• FDA review is nearing a key decision: D-PLEX100’s priority-review PDUFA date is November 28, with labeling discussions underway and scheduled FDA interactions described as on track. Approval and the planned early-2027 launch remain subject to FDA action; the company did not discuss inspection details.
• PolyPid and Azurity are preparing for a U.S. launch, with Azurity building its commercial teams and targeting hospitals. The company cautioned that formulary reviews happen account by account and adoption may take several months; a CMS decision on NTAP reimbursement is expected in August 2027.
• Label expansion is a potential growth driver: PolyPid plans to begin FDA discussions this quarter on expanding D-PLEX100 beyond colorectal surgery to broader abdominal procedures. The company has not yet received FDA feedback on what evidence or requirements would be needed.
• The EMA validated PolyPid’s D-PLEX100 application and began its review, with a decision expected in the second half of 2027. After ending its European agreement with ADVANZ PHARMA, PolyPid regained commercialization rights and said it is discussing potential partnerships.
• PolyPid reported $15.5 million in cash and short-term deposits at quarter-end and said it received a further $15 million Azurity payment in early October; management expects resources to fund operations into 2028. The company also plans PD01B’s pre-IND meeting and first-in-human study in the second half of 2027, while the program remains in development.

PolyPid Stock Performance

PolyPid stock traded up $0.30 during midday trading on Wednesday, reaching $6.62. 359,090 shares of the stock were exchanged, compared to its average volume of 125,961. PolyPid has a 52 week low of $3.50 and a 52 week high of $7.15. The firm has a market cap of $126.21 million, a PE ratio of -4.47 and a beta of 1.43. The company's fifty day moving average is $5.30 and its 200-day moving average is $4.77.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of PolyPid in a research report on Friday, September 18th. Wall Street Zen upgraded PolyPid from a "hold" rating to a "buy" rating in a research report on Saturday, October 31st. HC Wainwright reiterated a "buy" rating and set a $13.00 price objective on shares of PolyPid in a research note on Tuesday, July 21st. Oppenheimer started coverage on PolyPid in a report on Tuesday, October 27th. They set an "outperform" rating and a $10.00 price objective on the stock. Finally, Craig Hallum set a $12.00 target price on PolyPid in a research note on Wednesday, July 22nd. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, PolyPid has an average rating of "Moderate Buy" and a consensus target price of $11.00.

PolyPid Company Profile

PolyPid Ltd. NASDAQ: PYPD is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company's technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure. PolyPid's lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company's proprietary PLEX polymeric matrix. It is being developed for the prevention of surgical-site infections, initially in patients undergoing colorectal surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.